Catholic Health Initiatives (CHI) is a national Catholic healthcare system, with headquarters in Englewood, Colorado. CHI is a nonprofit, faith-based health system formed, in 1996, through the consolidation of three Catholic health systems. It is one of the nation's largest healthcare systems.[citation needed] In February 2019, CHI merged with Dignity Health, forming CommonSpirit Health.
Introduction Adult Spinal Deformity (ASD) involves age-related lumbar degeneration and curvature. Treatment begins with therapy and pain management, but severe cases may need surgery. This study examines the impact of adjunctive spinal surgeries with fusion on surgical outcomes. Methods This study reviewed ASD patients undergoing long-segment thoracolumbar fusion. Patients were classified as fusion-only or adjunctive (laminectomy plus fusion). Propensity score matching (PSM) adjusted for cohort parameters. Primary outcomes were analyzed across four domains: blood loss, functional recovery, hospital length of stay (LOS) and operative complications using standardized treatment effects. Results After PSM (Adjunctive, n = 82; Fusion-only, n = 34), no significant differences were observed in anesthesia duration, blood loss metrics, transfusion volumes, or postoperative Oswestry Disability Index improvements between groups. However, adjunctive surgery was associated with delayed postoperative initiation of walking (mean difference: 0.66 days, 95%CI: 0.19-1.14; p = 0.006) and reduced risk of hardware failure (RD: -0.11, 95%CI: -0.23, -0.0; p = 0.047). No differences were found in rates of infections, pseudarthrosis or overall complication. Conclusion Adjunctive spine surgery showed delayed post-operative ambulation and reduced risk for hardware failure. However, functional improvement, overall complication rates and blood loss metrics were largely comparable. These findings suggest that adjunctive procedures may be safely performed when clinically indicated but should be selectively applied based on individual patient characteristics risk profiles and goals of surgery.
Introduction Pembrolizumab, an immune checkpoint inhibitor, has been shown to improve survival in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a significant tumor proportion score. However, emerging evidence suggests potential cardiotoxicity associated with pembrolizumab use. Despite this concern, cardiovascular outcomes in NSCLC patients receiving pembrolizumab remain underexplored. Methods We conducted a retrospective cohort study using data from the US Collaborative Network TriNetX, covering the period from January 2017 to January 2025. We identified NSCLC patients receiving chemotherapy and compared those treated with pembrolizumab to those who were not, excluding patients on other immune checkpoint inhibitors. Patients were identified using ICD-10 codes. Baseline characteristics—including demographics, comorbidities, laboratory values, and medication use—were balanced using propensity score matching to improve comparability between groups. Results After propensity score matching, 3,416 patients were included in each group, with no significant differences in baseline characteristics or medication use. Over a five-year follow-up period, patients receiving pembrolizumab had a higher risk of heart failure (HR 1.463, 95% CI 1.238-1.729, P < 0.0001), major adverse cardiovascular events (HR 1.209, 95% CI 1.098-1.330, P = 0.0001), atrial arrhythmia (HR 1.394, 95% CI 1.168-1.664, P = 0.0002), and pericarditis (HR 1.989, 95% CI 1.670-2.369, P < 0.0001). However, the risk of ventricular arrhythmia did not differ significantly between the two groups (HR 1.153, 95% CI 0.832-1.596, P = 0.392). Conclusion Our study found that pembrolizumab use in NSCLC patients was associated with an increased risk of heart failure, MACE, atrial arrhythmia, and pericarditis. Further research is needed to develop strategies for monitoring and preventing these cardiovascular complications.
Introduction Patients with dilated cardiomyopathy (DCM) due to ischemic causes generally have a worse prognosis than those with non-ischemic DCM. While emerging data suggest comparable short-term outcomes after transcatheter edge-to-edge mitral valve repair (TEER) between these two groups, the long-term prognosis remains uncertain. Methods We conducted a retrospective cohort study using data from the US Collaborative Network TriNetX, spanning January 2010 to January 2025. Patients with DCM who underwent TEER were identified and categorized into ischemic and non-ischemic DCM groups. Baseline characteristics, including demographics, comorbidities, laboratory findings, and medication use, were adjusted using propensity score matching to ensure comparability. The primary outcome was five-year all-cause mortality, with secondary outcomes including adverse cardiovascular and renal outcomes. Results After propensity score matching, 539 patients were included in each group, with no significant differences in baseline characteristics or medication use. Over five years, all-cause mortality was similar between ischemic and non-ischemic DCM groups (HR 1.195, 95% CI 0.956-1.493, P = 0.1168). However, ischemic DCM patients had higher rates of acute myocardial infarction (HR 1.663, 95% CI 1.219-2.269, P = 0.0012), heart failure exacerbation (mean 10.5 vs. 6.8 episodes, P = 0.0005), ventricular arrhythmia (HR 1.494, 95% CI 1.219-1.832, P < 0.001), cardiogenic shock (HR 1.535, 95% CI 1.1143-2.06, P = 0.0041), and AKI (HR 1.238, 95% CI 1.038-1.477, P = 0.0171). Stroke (HR 0.921, 95% CI 0.622-1.363, P = 0.6791) and atrial fibrillation (HR 0.901, 95% CI 0.779-1.041, P = 0.1586) occurred at similar rates in both groups. Conclusion Among patients with DCM undergoing TEER, those with ischemic cardiomyopathy had higher rates of MI, heart failure exacerbation, ventricular arrhythmia, cardiogenic shock, and AKI. However, all-cause mortality, stroke, and atrial fibrillation rates were comparable between groups. These findings underscore the need for close long-term monitoring in ischemic DCM patients post-TEER.
Malware dynamic analysis performed by experts provides useful information regarding behavior, connection destinations, and samples after de-obfuscation at a relatively low cost. On the other hand, since practical malware analysis is tacit knowledge, the tasks to be performed in detailed analysis and the problems in performing these tasks are not always clearly defined. Adequate clarification of tasks and problems is expected to promote both the efficient training of analysts and research in this field. The purpose of this study is to clarify the tasks conducted by analysts, the end-conditions of these tasks, and the problems in task implementation. Eleven participants were interviewed and 63 different tasks and 25 different end-conditions of analysis tasks were identified. We also developed a basic analysis flow with the main purpose of providing support for the analysis procedure. In addition, with the aim of contributing to the efficiency of the training and self-improvement of analysts, we identified trends in the tasks and end-conditions of analysts with different experience levels and developed a basic analysis flow to support analysis procedures. We also presented knowledge related to education, such as the provision of training that encourages analysis from a more bird’s eye viewpoint. We identified 27 problems faced by analysts and demonstrated the need for support to ensure the safety of the dynamic analysis environment and to improve the information obtained through practical dynamic analysis. We believe our findings will be useful when drawing up educational guidelines for malware analysts and for future research related to dynamic analysis.